Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest

Fig. 3

Heterogeneity of marker expression in CTCs in blood samples from patients with mCRPC and resistance to ARI therapy. (A) Bright-field (BF) and immunofluorescence images of CTCs and WBCs isolated with VTX-1 from patient blood samples immuno-stained for DNA (DAPI, blue), cytokeratins (CK, green), and CD45 (red). Scale bar: 20 μm. (B) Number of CTCs per mL of blood. mCRPC: metastatic castration-resistant prostate cancer; ARI: androgen receptor inhibitor; CTCs: circulating tumor cells; WBCs: white blood cells

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us